NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation

NCT05918042

CompletedN/A

Sponsor: AstraZeneca

Conditions: Ovarian Cancer

Countries: Russia

Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history. It is estimated that approximately 400 patients will be enrolled in approximately 25 sites. Demographic and clinical characteristics, treatment approaches and outcomes in HRD+ patients with high-grade epithelial ovarian, primary peritoneal, and/or fallopian tube cancer will be collected at baseline and on prospective visits.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients ≥18 years of age;
* Willing and ability to provide written informed consent for participation in the study;
* Known status HRD+ (positive BRCAm test and/or positive Genomic Instability test);
* Patients with histologically confirmed diagnosis of high-grade IC-IV FIGO stages epithelial ovarian, primary peritoneal, and/or fallopian tube cancer;
* Completed primary treatment (surgery and/or 1st line CT +/- bevacizumab) no more than 3 months after completion of primary treatment.

Exclusion Criteria:

* Patients participating in other clinical studies

Locations (24)

Arkhangelsk, Russia
Barnaul, Russia
Chelyabinsk, Russia
Grozny, Russia
Irkutsk, Russia
Izhevsk, Russia
Kaliningrad, Russia
Kaluga, Russia
Krasnodar, Russia
Krasnoyarsk, Russia
Lyubertcy, Russia
Moscow, Russia
N.Novgorod, Russia
Nal'chik, Russia
Novosibirsk, Russia
Omsk, Russia
Saint Petersburg, Russia
Saratov, Russia
Sochi, Russia
Tomsk, Russia
Ufa, Russia
Vladivostok, Russia
Yakutiya, Russia
Yaroslavl, Russia